NICE INSIGHT REPORT
Antibody–Drug Conjugate, ADC:2024 Market Insight, CDMO Pricing and Competitor Benchmarking
Launching September 2024
- 2024 CDMO pricing data for competitive benchmarking
- ADC manufacturing process and areas of innovation
- 30+ company profiles for a comprehensive CDMO landscape
- 100+ pages of ADC market insights and breakthroughs
- Projections on one of the most anticipated markets
Key market insights for innovators, CDMOs and investors in the Antibody–Drug Conjugate industry.
The market trends that decision makers need to know
Our complete Market Analysis uses scientific insights from PhDs and researchers to provide an exhaustive overview of the ADC industry. From the emergence of ADCs as cancer treatments to how big pharma has penetrated ADC, stay ahead of market trends with our report.
Exclusive pricing data to benchmark against peers
Keep your sales team ahead of the curve by using our primary data for an accurate pricing comparison. Our Market Analysis provides a manufacturing process and strategic pricing study designed to give CDMOs a competitive edge.
Launching September 2024
Market intelligence for research, manufacturing and pricing all in one report.The Antibody–Drug Conjugate, ADC: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking provides
Current pricing data for benchmarking in the emerging market
Manufacturing technologies that are invaluable for ADC manufacturers
Hundreds of pages of market insights for your sales team
30+ company profiles of top CDMOs in the U.S., Europe and Asia
Pipeline overview and the approval and regulatory landscape
Value-chain analysis and the unique complexities in ADC production